Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis

References

• RozenblitMLebwohlMNew biologics for psoriasis and psoriatic arthritisDermatol Ther2009221566019222517
   PubMed Web of Science ®Google Scholar
• BilacCErmertcanATBilacDBDeveciAHorasanGDThe relationship between symptoms and patient characteristics among psoriasis patientsIndian J Dermatol Venereol Leprol200975555119736461
   PubMed Web of Science ®Google Scholar
• Van VoorheesASFriedRDepression and quality of life in psoriasisPostgrad Med2009121415416119641281
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundationhttp://www.psoriasis.org/netcommunity/learn_statistics Accessed Dec 19, 2009.
   Google Scholar
• TesmerLALundySKSarkarSFoxDATh17 cells in human diseaseImmunol Rev20082238711318613831
   PubMed Web of Science ®Google Scholar
• MurphyKMReinerSLThe lineage decisions of helper T cellsNat Rev Immunol200221293394412461566
   PubMed Web of Science ®Google Scholar
• ChienALElderJTEllisCNUstekinumab: a new option in psoriasis therapyDrugs20096991141115219537833
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity200013571572511114383
   PubMed Web of Science ®Google Scholar
• StockingerBVeldhoenMDifferentiation and function of Th17 T cellsCurr Opin Immunol200719328128617433650
   PubMed Web of Science ®Google Scholar
• HarringtonLEHattonRDManganPRInterleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNat Immunol2005116111123113216200070
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet2009373966463364019217154
   PubMed Web of Science ®Google Scholar
• CuchacovichRSEspinozaLRUstekinumab for psoriatic arthritisLancet2009373966460560619217153
   PubMed Web of Science ®Google Scholar
• AsarchABarakOLooDSGottliebABTh17 cells: a new therapeutic target in inflammatory dermatosesJ Dermatolog Treat200819631832618626814
   PubMed Web of Science ®Google Scholar
• ZhengYValdezPADanilenkoDMInterleukin-22 mediates early host defense against attaching and effacing bacterial pathogensNat Med200814328228918264109
   PubMed Web of Science ®Google Scholar
• ZhengYDanilenkoDMValdezPInterleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosisNature2007445712864865117187052
   PubMed Web of Science ®Google Scholar
• ChanJRBlumenscheinWMurphyEIL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesisJ Exp Med2006203122577258717074928
   PubMed Web of Science ®Google Scholar
• NogralesKEZabaLCGuttman-YasskyETh17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBr J Dermatol200815951092110218684158
   PubMed Web of Science ®Google Scholar
• WolkKWitteEWallaceEIL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasisEur J Immunol20063651309132316619290
   PubMed Web of Science ®Google Scholar
• SiegemundSSchützeNSchulzSDifferential IL-23 requirement for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar EnteritidisInt Immunol200921555556519297659
   PubMed Web of Science ®Google Scholar
• SchulzSMKöhlerGSchützeNProtective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17J Immunol2008181117891790119017979
   PubMed Web of Science ®Google Scholar
• GodinezIRaffatelluMChuHInterleukin-23 orchestrates mucosal responses to Salmonella enterica serotype Typhimurium in the intestineInfect Immun200977138739818955477
   PubMed Web of Science ®Google Scholar
• EyerichSEyerichKPenninoDTh22 cells represent a distinct human T cell subset involved in epidermal immunity and remodelingJ Clin Invest2009119123573358519920355
   PubMed Web of Science ®Google Scholar
• TohyamaMHanakawaYShirakataYIL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expressionEur J Immunol200939102779278819731362
   PubMed Web of Science ®Google Scholar
• ToichiETorresGMcCormickTSAn anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasisJ Immunol20061177(7)4917492616982934
   PubMedGoogle Scholar
• GottliebABChamianFMasudSTNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaquesJ Immunol200517542721272916081850
   PubMed Web of Science ®Google Scholar
• ZabaLCCardinaleIGilleaudeauPAmelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJ Exp Med2007204133183319418039949
   PubMed Web of Science ®Google Scholar
• CargillMSchrodiSJChangMA large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesAm J Hum Genet200780227329017236132
   PubMed Web of Science ®Google Scholar
• CaponFDi MeglioPSzaubJSequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasisHum Genet2007122220120617587057
   PubMed Web of Science ®Google Scholar
• NairRPRuetherAStuartPEPolymorphisms of the IL12B and IL23R genes are associated with psoriasisJ Invest Dermatol200812871653166118219280
   PubMed Web of Science ®Google Scholar
• ChenXTanZYueQLiuHLiuZLiJThe expression of interleukin-23 (p19/p40) and inteleukin-12 (p35/p40) in psoriasis skinJ Huazhong Univ Sci Technolog Med Sci200626675075217357509
   PubMedGoogle Scholar
• PiskinGSylva-SteenlandRMBosJDTeunissenMBIn vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skinJ Immunol200617631908191516424222
   PubMed Web of Science ®Google Scholar
• LeeETrepicchioWLOestreicherJLIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisJ Exp Med2004199112513014707118
   PubMed Web of Science ®Google Scholar
• TsunemiYSaekiHNakamuraKInterleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgarisJ Dermatol Sci200230216116612413772
   PubMed Web of Science ®Google Scholar
• NairRPDuffinKCHelmsCGenome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysNat Genet200941219920419169254
   PubMed Web of Science ®Google Scholar
• WilsonNJBonifaceKChanJRDevelopment, cytokine profile and function of human interleukin 17-producing helper T cellsNat Immunol20078995095717676044
   PubMed Web of Science ®Google Scholar
• KauffmanCLAriaNToichiEA phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisJ Invest Dermatol200412361037104415610511
   PubMed Web of Science ®Google Scholar
• SobellJMKalbREWeinbergJMManagement of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agentsJ Drugs Dermatol20098323023819271369
   PubMedGoogle Scholar
• GottliebABCooperKDMcCormickTSA phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasisCurr Med Res Opin20072351081109217519075
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med2007356658059217287478
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
   PubMed Web of Science ®Google Scholar
• AlwawiEAKruligEGordonKBLong-term efficacy of biologics in the treatment of psoriasis: what do we really know?Dermatol Ther200922543144019845720
   PubMed Web of Science ®Google Scholar
• ZhuYHuCLuMPopulation pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasisJ Clin Pharmacol200949216217519179295
   PubMed Web of Science ®Google Scholar
• GriffithsCEMStroberBFidelus-GortRMenterAA Phase 3, Multicenter, Randomized Study Comparing Ustekinumab and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis. P33182009 AAD meetingSan Francisco
   Google Scholar
• BrandSCrohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s diseaseGut20095881152116719592695
   PubMed Web of Science ®Google Scholar
• KobayashiTOkamotoSHisamatsuTIL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s diseaseGut200857121682168918653729
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGFedorakRNA randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s diseaseGastroenterology200813541130114118706417
   PubMed Web of Science ®Google Scholar
• SegalBMConstantinescuCSRaychaudhuriARepeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging studyLancet Neurol20087979680418703004
   PubMed Web of Science ®Google Scholar
• CuaDJSherlockJChenYInterleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature2003421692474474812610626
   PubMed Web of Science ®Google Scholar
• TouilTFitzgeraldDZhangGXRostamiAMGranBPathophysiology of interleukin-23 in experimental autoimmune encephalomyelitisDrug News Perspect2006192778316628262
   PubMedGoogle Scholar
• SegalBMDwyerBKShevachEMAn interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune diseaseJ Exp Med199818745375469463404
   PubMed Web of Science ®Google Scholar
• LongbrakeEERackeMKWhy did IL-12/IL-23 antibody therapy fail in multiple sclerosis?Expert Rev Neurother20099331932119271940
   PubMed Web of Science ®Google Scholar
• MaCSChewGYSimpsonNDeficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3J Exp Med200820571551155718591410
   PubMed Web of Science ®Google Scholar
• MilnerJDBrenchleyJMLaurenceAImpaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndromeNature2008452718877377618337720
   PubMed Web of Science ®Google Scholar
• GrimbacherBHollandSMGallinJIHyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorderN Engl J Med1999340969270210053178
   PubMed Web of Science ®Google Scholar
• de JongRAltareFHaagenIASevere mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patientsScience19982805368143514389603733
   PubMed Web of Science ®Google Scholar
• AltareFDurandyALammasDImpairment of mycobacterial immunity in human interleukin-12 receptor deficiencyScience19982805368143214359603732
   PubMed Web of Science ®Google Scholar
• AltareFLammasDRevyPInherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infectionJ Clin Invest199810212203520409854038
   PubMed Web of Science ®Google Scholar
• FieschiCCasanovaJLThe role of interleukin-12 in human infectious diseases: only a faint signatureEur J Immunol20033361461146412778462
   PubMed Web of Science ®Google Scholar
• van de VosseEstherOttenhoffTHHuman host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunityMicrobes Infect2006841167117316513390
   PubMed Web of Science ®Google Scholar
• MacLennanCFieschiCLammasDAInterleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humansJ Infect Dis2004190101755175715499529
   PubMed Web of Science ®Google Scholar
• Filipe-SantosOBustamanteJChapgierAInborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical featuresSemin Immunol200618634736116997570
   PubMed Web of Science ®Google Scholar
• LebwohlMBagelJGelfandJMFrom the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisJ Am Acad Dermatol20085819410517980456
   PubMed Web of Science ®Google Scholar
• DohertySDVan VoorheesALebwohlMGNational Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agentsJ Am Acad Dermatol200859220921718485527
   PubMed Web of Science ®Google Scholar
• WeissJMSubleskiJJWiggintonJMWiltroutRHImmunotherapy of cancer by IL-12-based cytokine combinationsExpert Opin Biol Ther20077111705172117961093
   PubMed Web of Science ®Google Scholar
• LebwohlMPappKHanCUstekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trialBr J Dermatol2009119[Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• ZhouHHuCZhuYPopulation-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasisJ Clin Pharmacol20091123[Epub ahead of print]
   Google Scholar
• Stelara™ (ustekinumab) [package insert]. http://www.stelarainfo.com/stelarainfo/assets/pdf/PrescribingInformation.pdf Accessed Oct 1, 2009.
   Google Scholar
• MaedaASchneiderSWKojimaMBeissertSSchwarzTSchwarzAEnhanced photocarcinogenesis in interleukin-12-deficient miceCancer Res20066662962296916540644
   PubMed Web of Science ®Google Scholar
• MeeranSMMantenaSKMelethSElmetsCAKatiyarSKInterleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomasMol Cancer Ther20065482583216648552
   PubMed Web of Science ®Google Scholar
• Enbrel® (etanercept) [package insert]. http://www.enbrel.com/pdf/enbrel_pi.pdf Accessed Oct 12, 2009.
   Google Scholar
• Humira® (adalimumab) [package insert]. http://www.rxabbott.com/pdf/humira.pdf Accessed Oct 1, 2009.
   Google Scholar
• Remicade® (infliximab) [package insert]. http://www.remicade.com/remicade/assets/HCP_PPI.pdf Accessed Oct 12, 2009.
   Google Scholar
• Amevive® (alefacept) [package insert] http://www.astellas.us/docs/amevive.pdf Accessed Oct 12, 2009.
   Google Scholar